Potential beneficial effect of IFN-β1a and ocrelizumab in people with MS during the COVID-19 pandemic.

Stefan Todorović Slobodan VojinovićDejan SavićDejan Aleksić Miloš Danilović

Published in: Acta neurologica Belgica (2023)

This study provides evidence that IFN-β1a can reduce the frequency of COVID-19 infection and that two DMTs, driven mainly by the IFN-β1a effect, do not increase the risk of moderate/severe COVID-19.

Keyphrases

dendritic cells
immune response
coronavirus disease
sars cov
mass spectrometry
multiple sclerosis
ms ms
early onset
high intensity
drug induced